Table 1

Categorisation of patients by pharmacological therapy during the 3-month assessment period

CategoryTreatment options
Additional add-on therapies (previously step 3*)
  • LABA+1 or more: LTRA, LAMA, theophylline or chromones

  • ICS+1 or more: LABA, LTRA, LAMA or theophylline

  • LABA, LTRA, LAMA, theophylline or chromones

High-dose therapies (previously step 4*)
  • ≥800 µg ICS/LABA

  • ≥800 µg ICS

  • ≥800 µg ICS+1 or more: LABA, LAMA, LTRA or theophylline

Continuous or frequent use of oral steroids (previously step 5*)
  • ≥800 µg ICS, OCS+other treatment

  • ICS are in BDP equivalent dose.

  • *Corresponding names of categories in the 2014 British Thoracic Society/Scottish Intercollegiate Guidelines Network guidelines.

  • BDP, beclomethasone dipropionate; ICS, inhaled corticosteroids; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonists; OCS, oral corticosteroid.